Featured Research

from universities, journals, and other organizations

Metastatic brain tumor treatment could be on the horizon with use of SapC-DOPS

Date:
July 24, 2014
Source:
University of Cincinnati Academic Health Center
Summary:
A new study has provided hope that previously studied SapC-DOPS could be used for treatment of brain cancer that has spread. "These results support the potential of SapC-DOPS for the diagnosis and therapy of primary and metastatic brain tumors which is critically needed to increase survival rates of patients with this illness,” one researcher said.

Over half of patients being seen in the clinic for a diagnosed brain tumor have metastatic cancer, which has no treatment and detrimental outcomes in most cases.

Related Articles


However, a new Cincinnati Cancer Center (CCC) study, published in the advance online edition of the journal Oncotarget, provides hope that previously studied SapC-DOPS could be used for treatment of brain cancer that has spread.

Xiaoyang Qi, PhD, member of the CCC, associate director and associate professor in the division of hematology oncology at the University of Cincinnati (UC) College of Medicine and a member of the UC Cancer and Neuroscience Institutes and the Brain Tumor Center, says this critical data shows promise for finding treatment for one of the deadliest cancers.

A lysosomal protein saposin C (SapC), and a phospholipid, known as dioleoylphosphatidylserine (DOPS), can be combined and assembled into tiny cavities, or nanovesicles, to target and kill many forms of cancer cells.

Lysosomes are membrane-enclosed organelles that contain enzymes capable of breaking down all types of biological components; phospholipids are major components of all cell membranes and form lipid bilayers -- or cell membranes.

Qi says his lab and collaborators have previously found that the combination of these two natural cellular components, called SapC-DOPS, caused cell death in cancer cell types, including brain, lung, skin, prostate, blood, breast and pancreatic cancer, while sparing normal cells and tissues.

"In spite of significant advances in understanding of the biology of tumors in the body, the translation of this knowledge to new and effective therapeutic strategies has been slow," he says. "As a consequence, brain tumors, either primary -- known as glioblastoma multiforme, the most aggressive and prevalent malignant brain tumor -- or secondary (metastatic), remain among the most untreatable and fatal of all cancers."

He adds that brain metastases arising from primary lung, skin and breast cancers affect about 10 to 30 percent of adult cancer patients and are much more prevalent than primary brain tumors.

"Although new targeted therapies are showing promising results, the difficulty in diagnosing and effectively targeting micrometastases -- multifocal small tumors that form as a result of the primary tumor -- makes the treatment of brain metastases one of the most pressing challenges in clinical oncology," Qi says, adding that it's often hard to both image the smaller tumors and to operate on them. "In this study, we evaluated the ability of SapC-DOPS to selectively target brain metastases of human breast and lung cancer cells in cultures and in animal models."

Using two groups of models -- one injected with a placebo and the other injected with SapC-DOPS -- researchers found that those receiving treatment with the nanovesicles had an extended life. Within the animal models, two were completely cured from the brain tumor and resulting metastasis. Scientists were able to monitor the uptake of SapC-DOPS by the tumors and their progression by using immunofluorescence imaging of brain sections.

Within 24 hours of injection, imaging showed that SapC-DOPS targeted the tumors and began to work.

"Because metastatic tumors in these models were generated and did not arise naturally from primary tumors, our models do not represent true metastases. However, they still reiterate the essential steps of the metastatic process," Qi says. "We were still able to show the antitumor effects of SapC-DOPS on human brain tumor cells in models and that SapC-DOPS selectively targets tumor cells in models with brain micrometastases derived from human breast or lung cancer cells. We also showed that SapC-DOPS has cytotoxic effects on metastatic breast cancer cells in cultures.

"These results support the potential of SapC-DOPS for the diagnosis and therapy of primary and metastatic brain tumors which is critically needed to increase survival rates of patients with this illness."


Story Source:

The above story is based on materials provided by University of Cincinnati Academic Health Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Blanco Vm, Chu Z, Vallabhapurapu Sd, Sulaiman Mk, Kendler A, Rixe O, Warnick Re, Franco Rs, Qi X. Phosphatidylserine-selective targeting and anticancer effects of SapC-DOPS nanovesicles on brain tumors. Oncotarget, July 2014

Cite This Page:

University of Cincinnati Academic Health Center. "Metastatic brain tumor treatment could be on the horizon with use of SapC-DOPS." ScienceDaily. ScienceDaily, 24 July 2014. <www.sciencedaily.com/releases/2014/07/140724112556.htm>.
University of Cincinnati Academic Health Center. (2014, July 24). Metastatic brain tumor treatment could be on the horizon with use of SapC-DOPS. ScienceDaily. Retrieved December 19, 2014 from www.sciencedaily.com/releases/2014/07/140724112556.htm
University of Cincinnati Academic Health Center. "Metastatic brain tumor treatment could be on the horizon with use of SapC-DOPS." ScienceDaily. www.sciencedaily.com/releases/2014/07/140724112556.htm (accessed December 19, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, December 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Best Tips to Curb Holiday Carbs

The Best Tips to Curb Holiday Carbs

Buzz60 (Dec. 19, 2014) It's hard to resist those delicious but fattening carbs we all crave during the winter months, but there are some ways to stay satisfied without consuming the extra calories. Vanessa Freeman (@VanessaFreeTV) has the details. Video provided by Buzz60
Powered by NewsLook.com
Sierra Leone Bikers Spread the Message to Fight Ebola

Sierra Leone Bikers Spread the Message to Fight Ebola

AFP (Dec. 19, 2014) More than 100 motorcyclists hit the road to spread awareness messages about Ebola. Nearly 7,000 people have now died from the virus, almost all of them in west Africa, according to the World Health Organization. Video provided by AFP
Powered by NewsLook.com
Researchers Test Colombian Village With High Alzheimer's Rates

Researchers Test Colombian Village With High Alzheimer's Rates

AFP (Dec. 19, 2014) In Yarumal, a village in N. Colombia, Alzheimer's has ravaged a disproportionately large number of families. A genetic "curse" that may pave the way for research on how to treat the disease that claims a new victim every four seconds. Duration: 02:42 Video provided by AFP
Powered by NewsLook.com
Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Buzz60 (Dec. 19, 2014) A double-amputee makes history by becoming the first person to wear and operate two prosthetic arms using only his mind. Jen Markham has the story. Video provided by Buzz60
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins